B-Disease	0	8	Diabetic
I-Disease	9	20	retinopathy
O	20	21	,
O	22	29	present
O	30	33	and
O	34	40	future
O	40	41	.

O	42	52	Conclusion
O	53	55	of
B-Disease	56	64	diabetic
I-Disease	65	76	retinopathy
O	77	86	symposium
O	86	87	.

O	89	92	The
O	93	102	preceding
O	103	110	reports
O	111	113	of
O	114	117	the
B-Disease	118	126	Diabetic
I-Disease	127	138	Retinopathy
O	139	148	Symposium
O	149	152	are
O	153	161	reviewed
O	161	162	.

B-Disease	163	171	Diabetic
I-Disease	172	183	retinopathy
O	184	194	progresses
O	195	199	with
O	200	203	the
O	204	212	duration
O	213	215	of
O	216	223	disease
O	224	227	and
O	228	233	often
O	234	241	results
O	242	244	in
B-Disease	245	258	proliferative
I-Disease	259	270	retinopathy
O	271	273	in
O	274	277	the
B-Characteristic	278	286	juvenile
I-Characteristic	287	292	onset
O	293	300	patient
O	301	304	and
B-Disease	305	312	macular
I-Disease	313	318	edema
O	319	321	in
O	322	325	the
B-Characteristic	326	331	older
I-Characteristic	332	337	onset
O	338	345	patient
O	345	346	.

B-Diagnostic_tool	347	355	Periodic
I-Diagnostic_tool	356	371	ophthalmoscopic
I-Diagnostic_tool	372	384	examinations
O	385	388	are
O	389	398	essential
O	399	401	in
O	402	411	detecting
O	412	415	the
O	416	427	progression
O	428	430	of
B-Disease	431	442	retinopathy
O	443	446	and
O	447	458	development
O	459	461	of
O	462	469	disease
O	470	485	characteristics
O	486	491	which
O	492	500	indicate
O	501	502	a
O	503	507	need
O	508	511	for
O	512	521	treatment
O	521	522	.

O	523	533	Laboratory
O	534	537	and
O	538	546	clinical
O	547	557	experience
O	558	564	stress
O	565	568	the
O	569	579	importance
O	580	582	of
O	583	588	rigid
O	589	596	glucose
O	597	604	control
O	605	607	in
O	608	618	preventing
B-Disease	619	627	diabetic
I-Disease	628	639	retinopathy
O	639	640	.

B-Symptom	641	649	Ischemia
I-Symptom	650	652	of
I-Symptom	653	656	the
I-Symptom	657	670	midperipheral
I-Symptom	671	677	retina
O	678	688	stimulates
O	689	692	the
O	693	704	development
O	705	707	of
O	708	712	high
O	713	717	risk
O	718	725	factors
O	726	729	for
O	730	735	which
O	736	746	panretinal
O	747	763	photocoagulation
O	764	766	is
O	767	776	indicated
O	777	784	despite
O	785	789	side
O	790	797	effects
O	798	802	such
O	803	805	as
B-Symptom	806	815	decreased
I-Symptom	816	820	dark
I-Symptom	821	831	adaptation
O	831	832	.

O	833	837	Pars
O	838	843	plana
O	844	854	vitrectomy
O	855	862	results
O	863	865	in
O	866	877	substantial
O	878	884	visual
O	885	896	improvement
O	897	899	in
B-Anatomy	900	904	eyes
O	905	909	with
B-Symptom	910	921	nonclearing
I-Symptom	922	930	vitreous
I-Symptom	931	941	hemorrhage
O	942	945	and
O	945	946	/
O	946	948	or
B-Symptom	949	957	traction
I-Symptom	958	965	retinal
I-Symptom	966	977	detachments
I-Symptom	978	987	involving
I-Symptom	988	991	the
I-Symptom	992	998	macula
O	998	999	.

O	1000	1006	Future
O	1007	1015	advances
O	1016	1018	in
O	1019	1022	our
O	1023	1032	knowledge
O	1033	1035	of
B-Disease	1036	1044	diabetic
I-Disease	1045	1056	retinopathy
O	1057	1063	should
O	1064	1068	come
O	1069	1073	from
O	1074	1077	the
O	1078	1086	National
B-Anatomy	1087	1090	Eye
O	1091	1100	Institute
O	1100	1101	'
O	1101	1102	s
O	1103	1116	Collaborative
B-Disease	1117	1125	Diabetic
I-Disease	1126	1137	Retinopathy
O	1138	1148	Vitrectomy
O	1149	1154	Study
O	1155	1158	and
O	1159	1164	Early
O	1165	1174	Treatment
B-Disease	1175	1183	Diabetic
I-Disease	1184	1195	Retinopathy
O	1196	1201	Study
O	1201	1202	,
O	1203	1206	and
O	1207	1210	the
O	1211	1219	analysis
O	1220	1222	of
B-Symptom	1223	1236	vasoformative
I-Symptom	1237	1244	factors
O	1244	1245	.
